Syncona Limited 2017 Dividend Scrip Reference Price

 
TIDMSYNC 
 
31 July 2017 
 
                                Syncona Limited 
 
                      2017 dividend scrip reference price 
 
The Board of Syncona Limited (the "Company") announces that the scrip reference 
price for the Company's 2017 dividend will be GBP1.7184.  This is the higher of 
(i) the prevailing average of the middle market quotations of the Shares 
derived from the Daily Official List of the London Stock Exchange for the 
ex-dividend date, 20 July 2017, and the four subsequent dealing days and (ii) 
the net asset value per Share of the Company as at 30 June 2017. 
 
[ENDS] 
 
Enquiries 
 
Northern Trust International Fund Administration Services (Guernsey) Limited 
Company Secretary 
Tel:       [phone] 
 
 
Copies of this announcement and other corporate information can be found on the 
company website at:www.synconaltd.com 
 
About Syncona: 
 
Syncona is a leading FTSE250 healthcare company focused on investing in and 
building global leaders in life science. Our vision is to deliver 
transformational treatments to patients in truly innovative areas of healthcare 
while generating superior returns for shareholders. Our current investment 
portfolio consists of seven high quality companies in life science and a 
leading range of fund investments. 
 
We seek to partner with the best, brightest and most ambitious minds in science 
to build globally competitive businesses. We are established leaders in gene 
therapy, cell therapy and advanced diagnostics, and focus on delivering 
dramatic efficacy for patients in areas of high unmet need. 
 
Our market leading funds portfolio seeks to generate superior returns by 
investing in long only and alternative investment funds. This represents a 
productively deployed evergreen funding base which enables us to take a long 
term approach to investing in life sciences as we target the best new 
opportunities and support our existing portfolio companies to grow and succeed. 
 
Syncona is aligned with two of the premium charitable funders in UK science, 
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both 
of which are significant shareholders in our business.  We make a donation of 
0.3% of Net Asset Value to a range of charities each year. 
 
 
 
END 
 

(END) Dow Jones Newswires

July 31, 2017 11:39 ET (15:39 GMT)